Asia Pacific Melanoma Therapeutics Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$1,077.8

Forecast, 2030 (US$M)

$2,317.5

CAGR, 2024 - 2030

11.6%

Report Coverage

Asia Pacific

Asia Pacific melanoma therapeutics market, 2018-2030 (US$M)

Related Markets

Global Melanoma Therapeutics Industry Outlook

North America Melanoma Therapeutics Market Outlook

Europe Melanoma Therapeutics Market Outlook

Latin America Melanoma Therapeutics Market Outlook

MEA Melanoma Therapeutics Market Outlook

Asia Pacific melanoma therapeutics market highlights

The Asia Pacific melanoma therapeutics market generated a revenue of USD 1,077.8 million in 2023.
The market is expected to grow at a CAGR of 11.6% from 2024 to 2030.
In terms of segment, branded drugs was the largest revenue generating drug type in 2023.
Branded Drugs is the most lucrative drug type segment registering the fastest growth during the forecast period.

Asia Pacific data book summary

Market revenue in 2023	USD 1,077.8 million
Market revenue in 2030	USD 2,317.5 million
Growth rate	11.6% (CAGR from 2023 to 2030)
Largest segment	Branded drugs
Fastest growing segment	Branded Drugs
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Branded Drugs
Key market players worldwide	Bristol-Myers Squibb Co, AstraZeneca PLC, Novartis AG ADR, Merck & Co Inc, Amgen Inc, Roche, Abbott Laboratories

Other key industry trends

In terms of revenue, Asia Pacific region accounted for 19.5% of the global melanoma therapeutics market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 2,317.5 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Melanoma Therapeutics Market Scope

Melanoma therapeutics market segmentation & scope

Drug Type

Branded Drugs

Generic Drugs

Regions

Europe

Countries

U.S.

Canada

Spain

Sweden

Norway

Italy

Germany

France

Denmark

Argentina

Brazil

Mexico

Saudi Arabia

South Africa

UAE

Kuwait

Thailand

South Korea

Japan

India

China

Australia

Melanoma Therapeutics Market Companies

Name	Profile	# Employees	HQ	Website

Asia Pacific melanoma therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to melanoma therapeutics market will help companies and investors design strategic landscapes.

Branded drugs was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific melanoma therapeutics market based on branded drugs covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Asia Pacific melanoma therapeutics market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific melanoma therapeutics market databook

Our clientele includes a mix of melanoma therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific melanoma therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific melanoma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list